Enzo Biochem, Inc. (ENZ) Reports Q3 Loss of $0.09/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ENZ Hot Sheet
Price: $0.31 --0%
Financial Fact:
Clinical laboratory services: 18.56M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Clinical laboratory services: 18.56M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Enzo Biochem, Inc. (NYSE: ENZ) reported Q3 EPS of ($0.09), versus ($0.05) reported last year. Revenue for the quarter came in at $26 million, versus $25.8 million reported last year.
For earnings history and earnings-related data on Enzo Biochem, Inc. (ENZ) click here.
For earnings history and earnings-related data on Enzo Biochem, Inc. (ENZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
- Vistra stock sinks ahead of earnings report
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
